Building on the momentum of KRAS-specific cancer vaccines, a recent study introduced an innovative intranasal vaccine targeting NSCLC based on a mix of G12D mutant and wildtype KRAS peptides and enhanced by a nanoemulsion adjuvant [82]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.